Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Cigna shareholders approved the Express Scripts deal. Photo: Scott Eisen/Getty Images
Cigna shareholders voted by a large margin Friday to approve the health insurer's pending acquisition of pharmacy benefit manager Express Scripts.
Why it matters: This deal is one step closer to consolidating the big health insurers and the big pharmacy benefit managers under the same roof. The companies say that will save consumers money on prescription drugs, though some policy analysts and researchers are skeptical.
What's next: Today's vote was largely expected, after Carl Icahn dropped his opposition bid. Now the most important decision rests with Department of Justice antitrust officials, who are reviewing this deal as well as the CVS-Aetna merger.